Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
暂无分享,去创建一个
E. Lewis | T. Berl | R. Atkins | J. Lewis | E. Ritz | L. Hunsicker | W. Clarke | M. Pohl | J. Lewis | R. Rohde | I. Raz | E Ritz | E J Lewis | L G Hunsicker | W R Clarke | T Berl | M A Pohl | J B Lewis | R C Atkins | R Rohde | I Raz | E. Ritz | Robert C. Atkins | Lawrence G. Hunsicker | Edmond J Lewis | Tomas Berl | E. Lewis
[1] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[2] N. Hollenberg,et al. The paradox of the low-renin state in diabetic nephropathy. , 1999, Journal of the American Society of Nephrology : JASN.
[3] A. Fogo,et al. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. , 1993, Kidney international.
[4] M. Engelgau,et al. Diabetes trends in the U.S.: 1990-1998. , 2000, Diabetes care.
[5] G. Wolf,et al. Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells. , 1992, The American journal of pathology.
[6] T. Hedner,et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study , 1999, The Lancet.
[7] N. Hollenberg,et al. Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans. , 2000, Hypertension.
[8] B. Brenner,et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. , 1986, The Journal of clinical investigation.
[9] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .
[10] S. Kagami,et al. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. , 1994, The Journal of clinical investigation.
[11] E. Lewis,et al. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[12] Philip D. Harvey,et al. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 , 1998, BMJ.
[13] B Neal,et al. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.
[14] N. Hollenberg,et al. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men. , 1997, Hypertension.
[16] Robert F. Woolson,et al. Statistical Methods for the Analysis of Biomedical Data. , 1990 .
[17] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[18] K. K. Lan,et al. Discrete sequential boundaries for clinical trials , 1983 .
[19] G. Remuzzi,et al. Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. , 1999, Kidney international.
[20] C. Bulpitt,et al. Effects of Calcium-Channel Blockade in Older Patients with Diabetes and Systolic Hypertension , 1999 .
[21] M. Lishner,et al. Long-Term Stabilizing Effect of Angiotensin-Converting Enzyme Inhibition on Plasma Creatinine and on Proteinuria in Normotensive Type II Diabetic Patients , 1993, Annals of Internal Medicine.
[22] G. Remuzzi,et al. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. , 1998, Journal of the American Society of Nephrology : JASN.
[23] B. Davis,et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. , 1996, JAMA.
[24] G. Remuzzi,et al. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.